BEAM vs. CRSP, DNLI, EDIT, NTLA, TWST, VCYT, VRNA, RVMD, MRUS, and GRFS
Should you be buying Beam Therapeutics stock or one of its competitors? The main competitors of Beam Therapeutics include CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Twist Bioscience (TWST), Veracyte (VCYT), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Merus (MRUS), and Grifols (GRFS). These companies are all part of the "medical" sector.
Beam Therapeutics vs. Its Competitors
CRISPR Therapeutics (NASDAQ:CRSP) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.
CRISPR Therapeutics has higher earnings, but lower revenue than Beam Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, CRISPR Therapeutics had 10 more articles in the media than Beam Therapeutics. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 3 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.33 beat CRISPR Therapeutics' score of 0.28 indicating that Beam Therapeutics is being referred to more favorably in the news media.
69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 4.3% of CRISPR Therapeutics shares are held by insiders. Comparatively, 3.5% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
CRISPR Therapeutics has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500.
CRISPR Therapeutics presently has a consensus target price of $71.50, suggesting a potential upside of 5.55%. Beam Therapeutics has a consensus target price of $46.40, suggesting a potential upside of 80.19%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.
Beam Therapeutics has a net margin of -661.31% compared to CRISPR Therapeutics' net margin of -1,229.43%. CRISPR Therapeutics' return on equity of -20.05% beat Beam Therapeutics' return on equity.
Summary
Beam Therapeutics beats CRISPR Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Beam Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BEAM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Beam Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BEAM) was last updated on 10/5/2025 by MarketBeat.com Staff
Free BEAM Stock Alerts